Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety

(Length of presentation: 26 minutes)
 
Badrinath Konety presents  “Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry”.  Blue light cystoscopy (BLC) using hexaminolevulinate HCL (Cysview®) has been previously shown to improve detection of non-muscle-invasive bladder cancer (NMIBC).  The objective of this study was to evaluate the detection of malignant lesions in a heterogenous group of patients in the real world setting and document the change in risk category due to upstaging or upgrading.  Dr. Konety summarizes the key points about the registry and the study findings.  Blue Light Cystoscopy with hexaminolevulinate HCL significantly increases detection rates of CIS and papillary lesions compared to White Light Cystoscopy alone and can result in upstaging or upgrading in about 14% of patients. Further, he says repeat use of Cysview® for Blue Light Cystoscopy is safe.



Biography:

Badrinath Konety, MD, MBA, serves as CEO of University of Minnesota Physicians as well as Vice Dean for Clinical Affairs at the University of Minnesota Medical School. Dr. Konety is a professor in the Department of Urology where he holds the Dougherty Family Chair in Uro-Oncology and Director of the Institute for Prostate and Urologic Cancers. He is also the Assoicate Director of Clinical Research at the Masonic Cancer Center (MCC) at the University of Minnesota. 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe